Skip to Content

Morphic Holding, Inc.

Company NameMorphic Holding, Inc.
Stock SymbolMORF

On September 22, 2023, Morphic issued a press release announcing publication of an abstract discussing the Company’s EMERALD-1 phase 2a primary results. The Company revealed disappointing results, including that “endoscopic improvement was achieved in 25.7% of patients at week 12,” which was less than the 41% shown by Entyvio.

On this news, Morphic’s stock price fell $28.26, or 54.4%, over two consecutive trading days to close at $23.14 per share on September 25, 2023, thereby injuring investors.

Submit Your Information

If you suffered a loss on your Morphic Holding, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.

Shares Purchased

Number of SharesBuy DatePrice Per ShareAdd

Shares Sold

Number of SharesSell DatePrice Per ShareAdd